These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 22471322)

  • 1. Challenges of biomarkers in drug discovery and development.
    Goodsaid F
    Expert Opin Drug Discov; 2012 Jun; 7(6):457-61. PubMed ID: 22471322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker qualification pilot process at the US Food and Drug Administration.
    Goodsaid F; Frueh F
    AAPS J; 2007 Mar; 9(1):E105-8. PubMed ID: 17408233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization.
    Amur S; LaVange L; Zineh I; Buckman-Garner S; Woodcock J
    Clin Pharmacol Ther; 2015 Jul; 98(1):34-46. PubMed ID: 25868461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promises of biomarkers in drug development--a reality check.
    Marrer E; Dieterle F
    Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory perspective on remaining challenges for utilization of pharmacogenomics-guided drug developments.
    Otsubo Y; Ishiguro A; Uyama Y
    Pharmacogenomics; 2013 Jan; 14(2):195-203. PubMed ID: 23327579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biomarkers: "Found in translation"].
    Lockhart BP; Walther B
    Med Sci (Paris); 2009 Apr; 25(4):423-30. PubMed ID: 19409197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualifying biomarkers for use in drug development: a US Food and Drug Administration overview.
    Woodcock J; Buckman S; Goodsaid F; Walton MK; Zineh I
    Expert Opin Med Diagn; 2011 Sep; 5(5):369-74. PubMed ID: 23484625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic analytical validation of commercial kits for the determination of novel biomarkers for clinical drug development.
    Nowatzke W; Cole TG; Bowsher RR
    Bioanalysis; 2010 Feb; 2(2):237-47. PubMed ID: 21083307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational medicine and the value of biomarker qualification.
    Goodsaid FM; Mendrick DL
    Sci Transl Med; 2010 Sep; 2(47):47ps44. PubMed ID: 20811041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Conference on Harmonisation; Guidance on E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Aug; 76(155):49773-4. PubMed ID: 21834216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualification of cardiac troponins for nonclinical use: a regulatory perspective.
    Hausner EA; Hicks KA; Leighton JK; Szarfman A; Thompson AM; Harlow P
    Regul Toxicol Pharmacol; 2013 Oct; 67(1):108-14. PubMed ID: 23876748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug development: from concept to marketing!
    Tamimi NA; Ellis P
    Nephron Clin Pract; 2009; 113(3):c125-31. PubMed ID: 19729922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for bringing drug delivery tools into discovery.
    Kwong E; Higgins J; Templeton AC
    Int J Pharm; 2011 Jun; 412(1-2):1-7. PubMed ID: 21421040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qualification of imaging biomarkers for oncology drug development.
    Waterton JC; Pylkkanen L
    Eur J Cancer; 2012 Mar; 48(4):409-15. PubMed ID: 22226478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.
    Jones HM; Chen Y; Gibson C; Heimbach T; Parrott N; Peters SA; Snoeys J; Upreti VV; Zheng M; Hall SD
    Clin Pharmacol Ther; 2015 Mar; 97(3):247-62. PubMed ID: 25670209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular biomarkers: a US FDA effort.
    Hong H; Goodsaid F; Shi L; Tong W
    Biomark Med; 2010 Apr; 4(2):215-25. PubMed ID: 20406066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Building a roadmap to biomarker qualification: challenges and opportunities.
    Amur SG; Sanyal S; Chakravarty AG; Noone MH; Kaiser J; McCune S; Buckman-Garner SY
    Biomark Med; 2015; 9(11):1095-105. PubMed ID: 26526897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translation of neurological biomarkers to clinically relevant platforms.
    Hayes RL; Robinson G; Muller U; Wang KK
    Methods Mol Biol; 2009; 566():303-13. PubMed ID: 20058180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.